Bai Tou Weng Tang (Pulsatilla Decoction)

Actions

Indications

Western Uses:

• What is Bai Tou Weng Tang used for in modern practice?

  In modern practice Bai Tou Weng Tang is referenced for acute infectious-type diarrheal illness with blood and pus in the stool — historically applied to patterns resembling bacillary dysentery (Shigella) and amoebic dysentery, conditions Western medicine recognizes by bloody, mucoid stool with cramping and urgency.

  These biomedical correlates describe the formula’s traditional use, not a claim that it treats any diagnosed disease. Contemporary research is preclinical, using mouse colitis models and network pharmacology to probe possible mechanisms (see research); it has not been studied in human clinical trials to our knowledge. Any use for a diagnosed condition, especially an acute infectious one, belongs with a qualified practitioner and appropriate medical care.

  Source: traditional-use correlates summarized from Bensky & Barolet, Formulas & Strategies; reference only, not a treatment claim.

Originally Appeared In:

• On Cold Damage (Shang Han Lun)

Notes:

• How is Bai Tou Weng Tang different from Shao Yao Tang and Ge Gen Huang Qin Huang Lian Tang?

  Bai Tou Weng Tang is reserved for more severe, purely heat-toxin dysentery with blood, whereas the other classic dysentery formulas address related but distinct patterns. Choosing between them depends on how much qi-and-blood stagnation, pain, and exterior involvement is present alongside the heat.

  • vs Shao Yao Tang (Peony Decoction): Shao Yao Tang treats damp-heat dysentery with more prominent qi-and-blood stagnation — marked abdominal pain and tenesmus — and includes blood-invigorating and qi-regulating herbs (Bai Shao, Dang Gui, Mu Xiang, Bing Lang) plus a small purgative (Da Huang) following the classic principle “to treat dysentery, regulate the qi and blood.” Bai Tou Weng Tang has no such herbs; it is a purer heat-toxin-clearing formula for more severe blood-in-the-stool presentations.
  • vs Ge Gen Huang Qin Huang Lian Tang (Kudzu, Scutellaria & Coptis Decoction): that formula addresses diarrhea/dysentery from heat trapped internally after improper treatment of an exterior condition, with residual fever and sweating — an exterior-interior heat pattern. Bai Tou Weng Tang has no exterior component; it is used for heat toxin already deep in the Intestines.

  Key modification: the classic variant Bai Tou Weng Jia Gan Cao E Jiao Tang (Jin Gui Yao Lue) adds Zhi Gan Cao and E Jiao to the base formula for dysentery occurring in a blood-deficient patient (classically postpartum) — protecting blood and yin while the four bitter-cold herbs still clear the heat toxin.

  Source: Bensky & Barolet, Formulas & Strategies (formula comparisons and the Jin Gui Yao Lue modification) + Sacred Lotus sources & references on pattern for Shao Yao Tang.

Clinical Studies & Research:

• Is there modern research on Bai Tou Weng Tang?

  Yes, but it is preclinical — mouse colitis models and network pharmacology rather than human clinical trials. Most recent work uses the formula (often called Baitouweng Tang/decoction in the literature) in dextran-sulfate-sodium (DSS) induced ulcerative colitis models to probe possible immune and barrier-repair mechanisms; a search of PubMed/PMC did not surface completed randomized clinical trials, so clinical-trial evidence should be treated as currently absent rather than assumed.

  • Immunomodulation (preclinical): in DSS-colitis mice, absorbed compounds (including anemoside A3, palmatine, and aesculin) bound therapeutic targets such as STAT3, JAK3, S1PR1, PD-1, and PD-L1 in molecular docking, and treatment reduced TNF-α and IL-6 while suppressing STAT3 activation (PMID 36434688; PMC 9701001).
  • Gut-barrier mechanism (preclinical): in DSS-colitis mice, the formula promoted DOPA decarboxylase (DDC) activity, shifting tryptophan metabolism toward indole metabolites that activate the aryl hydrocarbon receptor (AhR)/IL-22 pathway and strengthen intestinal barrier function (PMID 38974042; PMC 11224817).
  • TLR4/NF-κB pathway (preclinical): network pharmacology combined with a DSS mouse model found the formula reduced disease activity and colon shortening, lowered IL-6 and TNF-α, raised IL-10, and suppressed TLR4/NF-κB signaling (PMID 41736428).

  Sources: PubMed 36434688 / PMC 9701001; PubMed 38974042 / PMC 11224817; PubMed 41736428. Research context, not a therapeutic claim; evidence is preclinical and clinical-trial data appears limited or absent.